These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 26085527)

  • 41. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
    Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
    Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
    Ma Y; Sender S; Sekora A; Kong W; Bauer P; Ameziane N; Al-Ali R; Krake S; Radefeldt M; Weiss FU; Lerch MM; Parveen A; Zechner D; Junghanss C; Murua Escobar H
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457111
    [TBL] [Abstract][Full Text] [Related]  

  • 43. KRAS Pathways: A Potential Gateway for Cancer Therapeutics and Diagnostics.
    Tripathi PK; Mittal KR; Jain N; Sharma N; Jain CK
    Recent Pat Anticancer Drug Discov; 2024; 19(3):268-279. PubMed ID: 37038676
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.
    Kuracha MR; Thomas P; Loggie BW; Govindarajan V
    PLoS One; 2017; 12(6):e0179510. PubMed ID: 28640835
    [TBL] [Abstract][Full Text] [Related]  

  • 45. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 46. K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function.
    Alvarez-Moya B; López-Alcalá C; Drosten M; Bachs O; Agell N
    Oncogene; 2010 Nov; 29(44):5911-22. PubMed ID: 20802526
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Calmodulin disrupts plasma membrane localization of farnesylated KRAS4b by sequestering its lipid moiety.
    Grant BMM; Enomoto M; Back SI; Lee KY; Gebregiworgis T; Ishiyama N; Ikura M; Marshall CB
    Sci Signal; 2020 Mar; 13(625):. PubMed ID: 32234958
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in KRAS
    Tan YQ; Sun B; Zhang X; Zhang S; Guo H; Basappa B; Zhu T; Sethi G; Lobie PE; Pandey V
    Cell Death Dis; 2024 Feb; 15(2):173. PubMed ID: 38409090
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
    Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
    J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
    Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
    BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Non-Canonical Calmodulin Target Motif Comprising a Polybasic Region and Lipidated Terminal Residue Regulates Localization.
    Grant BMM; Enomoto M; Ikura M; Marshall CB
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326637
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α.
    Baer R; Cintas C; Dufresne M; Cassant-Sourdy S; Schönhuber N; Planque L; Lulka H; Couderc B; Bousquet C; Garmy-Susini B; Vanhaesebroeck B; Pyronnet S; Saur D; Guillermet-Guibert J
    Genes Dev; 2014 Dec; 28(23):2621-35. PubMed ID: 25452273
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Independent and core pathways in oncogenic KRAS signaling.
    Nussinov R; Tsai CJ; Jang H
    Expert Rev Proteomics; 2016 Aug; 13(8):711-6. PubMed ID: 27389825
    [No Abstract]   [Full Text] [Related]  

  • 54. Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
    Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
    Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biophysical and Structural Characterization of Novel RAS-Binding Domains (RBDs) of PI3Kα and PI3Kγ.
    Martinez NG; Thieker DF; Carey LM; Rasquinha JA; Kistler SK; Kuhlman BA; Campbell SL
    J Mol Biol; 2021 Apr; 433(8):166838. PubMed ID: 33539876
    [TBL] [Abstract][Full Text] [Related]  

  • 56. KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.
    Althaiban A; Thyagarajan A; Sahu RP
    Mini Rev Med Chem; 2023; 23(8):953-961. PubMed ID: 36573057
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The type of KRAS mutation drives PI3Kα/γ signalling dependency: Implication for the choice of targeted therapy in pancreatic adenocarcinoma patients.
    Cayron C; Guillermet-Guibert J
    Clin Res Hepatol Gastroenterol; 2021 Jan; 45(1):101473. PubMed ID: 32593694
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A cross-sectional study examining the expression of splice variants K-RAS4A and K-RAS4B in advanced non-small-cell lung cancer patients.
    Aran V; Masson Domingues P; Carvalho de Macedo F; Moreira de Sousa CA; Caldas Montella T; de Souza Accioly MT; Ferreira CG
    Lung Cancer; 2018 Feb; 116():7-14. PubMed ID: 29413054
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increased SPRY1 expression activates NF-κB signaling and promotes pancreatic cancer progression by recruiting neutrophils and macrophages through CXCL12-CXCR4 axis.
    Shi T; Li X; Zheng J; Duan Z; Ooi YY; Gao Y; Wang Q; Yang J; Wang L; Yao L
    Cell Oncol (Dordr); 2023 Aug; 46(4):969-985. PubMed ID: 37014552
    [TBL] [Abstract][Full Text] [Related]  

  • 60. α4-α5 Helices on Surface of KRAS Can Accommodate Small Compounds That Increase KRAS Signaling While Inducing CRC Cell Death.
    Abuasaker B; Garrido E; Vilaplana M; Gómez-Zepeda JD; Brun S; Garcia-Cajide M; Mauvezin C; Jaumot M; Pujol MD; Rubio-Martínez J; Agell N
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.